Immunicum AB Appoints Karin Hoogendoorn as Head of CMC

GOTHENBURG, Sweden, February 13, 2017 – Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced the appointment of Karin Hoogendoorn as Head of Chemistry, Manufacturing and Controls (CMC). Ms. Hoogendoorn, PharmD, is a seasoned expert in the development of biotechnological products and has lead successful CMC and CMC-regulatory efforts for a variety of products within positions at, among others, Novartis AG, Janssen Biologics BV and Crucell Holland BV. With her significant experience, especially in the cell and gene therapy field, she will support the Company in building CMC strategies for Immunicum’s platform technologies. She will report to Carlos de Sousa, CEO of Immunicum.

“The team at Immunicum welcomes Karin whose deep immersion in the biotechnology industry as well as years of experience working with chemistry, manufacturing and controls specifically for cell and gene therapy products will undoubtedly contribute top-level support and guidance to the Company,” said Carlos de Sousa, CEO of Immunicum. “We are looking forward to collaborating with Karin as Immunicum continues to develop our lead program, INTUVAX, and move it through clinical evaluation.”

“I am very pleased to have the opportunity to work alongside Carlos and his expert team at Immunicum,” said Karin Hoogendoorn. “It is a very dynamic time for Immunicum as the Company continues to evolve and expand, and I am enthusiastic about contributing to the development of the Company and its promising programs.”

Karin Hoogendoorn joins Immunicum with 20 years of experience within the biotechnology and pharmaceutical industry. Most recently, she served as Associate Director Regulatory CMC in the Cell and Gene therapy unit at Novartis AG where she was in charge of Global Regulatory CMC and overall CMC strategy for cell and gene therapies. She also spent seven years at Janssen Biologics BV (previously Centocor BV) as Associate Director Global Regulatory Affairs-CMC where she was responsible for writing and reviewing quality sections of regulatory dossiers for advanced therapy medicinal products (i.e. cell based medicinal products and combination products) and monoclonal antibodies. In the past, Karin also held different CMC roles at companies such as Crucell Holland BV and OctoPlus Development BV. Karin has a PharmD from Utrecht University, the Netherlands, and holds a MSc in Biology & Bio Pharmaceutical Sciences from Leiden University, the Netherlands. Apart from her role at Immunicum, Karin also serves as Senior Consultant CMC and CMC-RA at Quality RA BV in Leiden, the Netherlands.

About Immunicum AB (publ)
Immunicum AB (First North Premier: IMMU.ST) is a clinical stage company developing novel immuno-oncology therapies against a range of solid tumors. The Company’s lead compound, INTUVAX® is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. INTUVAX® was designed to combine the best of two worlds: a cost-effective cell-based (allogeneic) and off-the-shelf therapy that is capable of triggering a highly personalized and potentially long-lasting immune response against tumor cells throughout the body.

For more information, please contact
Carlos de Sousa, CEO, Immunicum
Ph: +46 (0) 31 41 50 52

Media Contact
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Ph: +49 89 2424 3494 or + 49 175 571 1562

The Company’s Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31

The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the company’s contact person on February 13, 2017 at 11.00 am CET

Keep reading

Immunicum Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Webcast